SEARCH

SEARCH BY CITATION

References

  • 1
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 2
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 88391.
  • 3
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 98192.
  • 4
    Eikelboom JW, Weitz JI. Update on antithrombotic therapy. New anticoagulants. Circulation 2010; 121: 152332.
  • 5
    Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 122.
  • 6
    Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492501.
  • 7
    Nagarakanti R, Ezekowitz MD, Oldgren J. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 1316.
  • 8
    Wang TJ, Parise H, Levy D, D’Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292: 24717.
  • 9
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 10
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 236372.
  • 11
    Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 6607.
  • 12
    Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 97583.
  • 13
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 2012; 125: 66976.
  • 14
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. a meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397402.
  • 15
    Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: medical. Stat Med 1989; 8: 44154.
  • 16
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. JAMA 1995; 273: 40812.
  • 17
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 18
    Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 25968.
  • 19
    European Medicines Agency (EMEA). European public assessment report: Pradaxa. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-PI-en.pdf Accessed 3 November 2009.
  • 20
    Boehringer Ingelheim. Boehringer Ingelheim’s Pradaxa available in US pharmacies starting Wednesday, November 3 [press release]. http://www.prnewswire.com/news-releases/boehringer-ingelheims-pradaxa-available-in-us-pharmacies-starting-Wednesday-November-3-106474818.html. Accessed 1 November 2010..
  • 21
    Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 12858.
  • 22
    Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 28595.
  • 23
    European Medicine Agency. Pradaxa summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 10 February 2012.
  • 24
    Harder S. Renal profiles of anticoagulants. J Clin Pharmacol 2012; 52: 96475.
  • 25
    Bayer Schering Pharma AG. Xarelto (Rivaroxaban) Summary of Product Characteristics. Berlin, Germany: Bayer Schering Pharma AG; 2009. Available at: http://www.xarelto.com/htlm/downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf. Accessed 2 February 2011.
  • 26
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 268996.
  • 27
    Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009; 101: 36772.
  • 28
    Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, Palareti G. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with VKA: results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 2012; 107: 11006.
  • 29
    Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 216875.
  • 30
    Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 919.
  • 31
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller H, Levi M. A randomized, placebo-controlled, crossover study in healthy subjects reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation 2011; 124: 15739.
  • 32
    BoehringerIngelheim Pharmaceuticals. RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed RE-LY trial. Updated 2011. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00808067?term=NCT00808067&rank=1; accessed 15 January 2012.